- InVivo Therapeutics (NVIV.OB -25%) tumbles after CEO/ CFO Francis Reynolds resigns due to a medical condition. The board has appointed Michael Astrue interim CEO. (PR)
- Not helping the stock is an article from SA contributor Biotech Sage, who says the shares are substantially overvalued and claims the "existing data and the company's proposed regulatory pathway" aren't enough to substantiate management's "bold assertions" regarding the "efficacy and market potential" of the company's scaffolding device.
InVivo slides as CEO resigns
Aug 23 2013, 15:45 ET